Please assess the completion status of the following clinical trial:

Trial Title: Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated BCR-ABL-positive ALL~* Age between 15 and 64 years~* Performance status between 0 and 3 (ECOG criteria)~* Adequate functioning of the liver (serum bilirubin level \< 2.0 mg/dL), kidneys (serum creatinine level \< 2.0 mg/dL), and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs)~* Written informed consent to participate in the trial~Exclusion Criteria:~* Uncontrolled active infection~* Another severe and/or life-threatening disease~* Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests~* Another primary malignancy which is clinically active and/or requires medical interventions~* Pregnant and/or lactating women~* Past history of renal failure

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).